



# REIMBURSEMENT POLICY STATEMENT INDIANA MARKETPLACE

| <b>Policy Name</b> | <b>Policy Number</b> | <b>Date Effective</b> |
|--------------------|----------------------|-----------------------|
| Drug Testing       | PY-0329              | 8/1/2019              |
| <b>Policy Type</b> |                      |                       |
| Medical            | Administrative       | Pharmacy              |
|                    |                      | <b>REIMBURSEMENT</b>  |







IV. Laboratory

- A. CareSource laboratories performing drug testing services must bill CareSource directly. **CareSource does not allow pass-through billing of services.** Any claim submitted by a provider which includes services ordered by that provider, but are performed by a person or entity other than that provider or a direct employee of that provider, is not billable to CareSource.

V. Non-Urine Testing

- A. CareSource will reimburse blood testing in emergency room settings.
- B. Drug testing with blood samples performed in any other setting outside of an emergency room is a non-covered benefit.
- C. Hair, saliva, or other body fluid testing for controlled substance monitoring has limited support in medical evidence and is not covered



2. Testing for pre-





|       |  |
|-------|--|
| G0659 | Drug testing definitive/Quantitative –non-specified number of drug classes<br>Drug testing (35)(32) IVE, TUE, THU, FRI, SAT, SUN (1) grade 7-10 (1) men (1) 18-65 (1) W/C De-Sub (1) train (1) 3<br>drugs and distinguish between structural isomers (but not necessarily stereoisomers),<br>including but not limited to, GC/MS (any type, single or tandem) and LC/MS (any |
|-------|--|



|       |   |
|-------|---|
| 80366 | pregabalin  |
| 80368 | sedative hypnotics (non benzodiazepines)              |
| 80369 | skeletal muscle relaxants 1 or 2                      |
| 80370 | skeletal muscle relaxants 3 or more                   |
| 80371 | stimulants, synthetic                                 |
| 80372 | tapentadol  |
| 80373 | tramadol  |
| 80374 | stereoisomer (enantiomer) analysis, single drug class |
| 80375 | drug, or substance definition                         |





- bin/retrieveECFR?gp=3&SID=7282616ac574225f795d5849935efc45&ty=HTML&h=L&n=pt42.1.8&r=PART#se42.1.8\_12
7. CareSource Evidence of Coverage and Health Insurance Contract. (2019). Retrieved on 4/29/2019 from <https://www.caresource.com/in/plans/marketplace/plan-documents/>
  8. Owen, G, Burton, A, Schade, C, Passik, S. (2012) Urine Drug Testing: Current Recommendations and Best Practices. *Pain Physician Journal*. Retrieved 12/13/2018 from <http://www.painphysicianjournal.com/current/pdf?article=MTcxMA%3D%3D&journal=68>
  9. U.S. Department of Veterans Affairs (2014) Pain Management Opioid Safety VA Educational Guide. Retrieved on 12/11/2018 from [https://www.va.gov/PAINMANAGEMENT/docs/OSI\\_1\\_Toolkit\\_Provider\\_AD\\_Educational\\_Guide\\_7\\_17.pdf](https://www.va.gov/PAINMANAGEMENT/docs/OSI_1_Toolkit_Provider_AD_Educational_Guide_7_17.pdf)
  10. Washington State Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain. (2017) Retrieved on 12/11/2018 from <https://kbml.ky.gov/prescribing-substance-abuse/Documents/Resources%20SAWashington%20State%20Interagency%20Guideline%20on%20Opioid%20Dosing%20for%20Chronic%20Non-Cancer%20Pain%20Urine%20Drug%20Testing%20Guidance.pdf>

The Reimbursement Policy Statement detailed above has received due consideration as defined in the Reimbursement

